Cargando…

Clinical features of SARS-CoV-2 Omicron BA.2; Lessons from previous observations – Correspondence

Detalles Bibliográficos
Autores principales:	Sahebi, Saeed, Keikha, Masoud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IJS Publishing Group Ltd. Published by Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252873/ https://www.ncbi.nlm.nih.gov/pubmed/35798207 http://dx.doi.org/10.1016/j.ijsu.2022.106754

Ejemplares similares

Clinical characteristics of human monkeypox laboratory confirmed cases: Lessons from observational studies
por: Sahebi, Saeed, et al.
Publicado: (2022)

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Cardiovascular disorders followed by SARS-CoV-2 infection: An inevitable challenge – Correspondence()
por: Rouhani, Jalil, et al.
Publicado: (2022)

BA.2.12.1 is a new omicron offshoot that is a highly contagious but not severe disease
por: Beheshti Namdar, Ali, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Human monkeypox coinfections; lessons from available cases – Correspondence
por: Karbalaei, Mohsen, et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5
por: Tan, Chee-Wah, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned?
por: Roohani, Jalil, et al.
Publicado: (2022)

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
por: Huo, Jiandong, et al.
Publicado: (2022)

Co-infection with SARS-CoV-2 omicron BA.1 and BA.2 subvariants in a non-vaccinated woman
por: Vatteroni, Maria Linda, et al.
Publicado: (2022)

BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
por: Tartof, Sara Y, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
por: Dijokaite-Guraliuc, Aiste, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Omicron Subvariants, Including BA.4 and BA.5, Substantially Preserve T Cell Epitopes of Ancestral SARS-CoV-2
por: Park, Kyemyung, et al.
Publicado: (2022)

Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection
por: Boucau, Julie, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Evidence of hantavirus circulation among the Iranian population: An emerging neglected tropical disease
por: Karbalaei, Mohsen, et al.
Publicado: (2022)

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination
por: Shen, Xiaoying, et al.
Publicado: (2022)

SARS-CoV-2 variant omicron XBB.1.5: challenges and prospects – correspondence
por: Channabasappa, Nikhil K., et al.
Publicado: (2023)

Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults
por: Brown, Patrick E., et al.
Publicado: (2022)

Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants
por: Malato, João, et al.
Publicado: (2022)

Deltacron is a recombinant variant of SARS-CoV-2 but not a laboratory mistake
por: Karbalaei, Mohsen, et al.
Publicado: (2022)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

The Omicron BA.2.2.1 subvariant drove the wave of SARS-CoV-2 outbreak in Shanghai during spring 2022
por: Ling, Yun, et al.
Publicado: (2022)

Is sexual intercourse a major route of human Monkeypox transmission mode? – Correspondence
por: Keikha, Masoud
Publicado: (2022)

Replicative capacity of SARS-CoV-2 omicron variants BA.5 and BQ.1.1 at elevated temperatures
por: Muramoto, Yukiko, et al.
Publicado: (2023)

Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2022)

The recently emerged BA.4 and BA.5 lineages of Omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic – Correspondence
por: Mohapatra, Ranjan K., et al.
Publicado: (2022)

Social networks and human monkeypox outbreak 2022: Hazards and opportunities – Correspondence
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients
por: Alcheikh, Ahmad, et al.
Publicado: (2023)

Implications of the SARS-CoV-2 subvariants BA.4 and BA.5
por: Rahimi, Farid, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2srupd8kam697oa0mamsl7r4ha